Erasca announced a clinical trial collaboration with Merck to evaluate ERAS-0015, a pan-RAS molecular glue, combined with Merck's KEYTRUDA (pembrolizumab) for treating RAS-mutant solid tumors. The study, called AURORAS-1, aims to improve treatment outcomes by targeting the RAS/MAPK pathway and enhancing immune response. Merck will supply KEYTRUDA at no cost, while Erasca sponsors the trial. This collaboration targets a large patient population with limited effective therapies and hopes to overcome resistance mechanisms in RAS-driven cancers.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
The producer price index (PPI) dropped by 0.3% in June following a slowdown in May, signaling easing inflation alongside a recent deflationary consumer price index (CPI) report. Real average hourly earnings rose 0.8% in June, marking the best wage ga...
President Donald Trump revealed that the US conducted another strike on Iran within 24 hours, aiming to dismantle the Iranian Revolutionary Guard Corps (IRGC), which he claims has lost about 90% of its weapons capabilities. Speaking at the Pennsylvan...
Ondo Finance announced the launch of the first tokenized equity representations using DTC tokenized entitlements, part of the DTCC Tokenization Service. This milestone pushed the ONDO token price up by about 5% and increased trading volume by 51.7% i...
